Biological age reversal, epigenetic clocks, senolytics, and anti-aging interventions
1.644 artigos
A monoclonal antibody targeting muscle-wasting pathways shows promise countering sarcopenia, inclusion body myositis, and GLP-1-induced lean mass loss.
Once considered an aging disease, sarcopenia now threatens children too — raising long-term metabolic and cardiovascular risks.
A novel NMN-delivering hydrogel microsphere targets mitochondria in muscle cells, reducing senescence and offering a new treatment path for sarcopenia.
Researchers identify LAMP1 on the cell surface as a reliable senescence biomarker, rising with age and in fibrotic lungs, enabling targeted senolytic therapy.
A comprehensive 2025 review maps how stress-cytokine GDF15 drives obesity, diabetes, heart failure, and aging—and how to target it therapeutically.
Podocyte FFAR4 deficiency drives kidney aging and glomerular disease via senescence and lipid toxicity; fish oil and TUG891 reverse damage.
Exendin-4 (a GLP-1R agonist like semaglutide) rejuvenates senescent macrophages after spinal cord injury, restoring debris clearance and promoting nerve repair.
A deep-learning analysis of 3,476 patients shows thymic health measured from routine CT scans strongly predicts immunotherapy outcomes across cancer types.
A massive single-cell study of 387,762 cells uncovers how thymic aging disrupts T cell development and reshapes peripheral immune function.
New research links exercise-driven upregulation of HMGCR to improved cardiac function and longer lifespan in aging Drosophila models.
A systematic review finds N-acetylcysteine improves muscle force and reduces oxidative stress—mostly in animals. Human trials are urgently needed.
Arsenic disrupts sirtuins — key NAD⁺-dependent longevity enzymes — accelerating aging and disease. New research maps the damage and points to fixes.
